Studies from University of Texas Health Science Center Houston Have Provided New Data on Neutropenia (Incidence and Risk Factors for Neutropenia After Intra-arterial Chemotherapy for Retinoblastoma).
In: Hematology Week, 2023-12-26, S. 1377-1377
serialPeriodical
Zugriff:
A new report from the University of Texas Health Science Center in Houston provides data on the incidence and risk factors for neutropenia after intra-arterial chemotherapy for retinoblastoma. Intra-arterial chemotherapy has become a popular treatment for retinoblastoma due to its reduced systemic toxicity and neutropenia. The study found that the incidence of severe neutropenia after intra-arterial chemotherapy was nearly 40%, higher than previously reported. Factors such as higher melphalan and topotecan doses were weakly correlated with a lower absolute neutrophil count. The researchers suggest that limiting topotecan doses, especially in combination with high melphalan doses, may help reduce the risk of neutropenia. [Extracted from the article]
Copyright of Hematology Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Studies from University of Texas Health Science Center Houston Have Provided New Data on Neutropenia (Incidence and Risk Factors for Neutropenia After Intra-arterial Chemotherapy for Retinoblastoma).
|
---|---|
Zeitschrift: | Hematology Week, 2023-12-26, S. 1377-1377 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1543-673X (print) |
Schlagwort: |
|
Sonstiges: |
|